目的 探討注射用硫普羅寧聯(lián)合注射用促肝細胞生長素治療慢性乙型肝炎的臨床效果。方法 選取2014年6月—2015年6月上海市奉賢區(qū)中心醫(yī)院收治的慢性乙型肝炎患者106例,隨機分為對照組和治療組,每組各53例。所有患者均給予常規(guī)治療,對照組給予注射用促肝細胞生長素100～120 mg,加入5%葡萄糖注射液250 mL中靜脈滴注,1次/d。治療組在對照組的基礎上給予注射用硫普羅寧0.2 g,加入5%葡萄糖注射液250 mL中靜脈滴注,1次/d。兩組患者均連續(xù)治療1個月。觀察兩組患者的臨床療效,檢測并比較兩組患者治療前后的肝功能指標和肝纖維化指標。結(jié)果 治療后,治療后,對照組和治療組總有效率分別為81.1%、96.2%,兩組總有效率比較差異具有統(tǒng)計學意義(P<0.05)。治療后兩組血清丙氨酸氨基轉(zhuǎn)移酶(ALT)、天冬氨酸氨基轉(zhuǎn)移酶(AST)、總膽紅素(TBIL)、谷氨酰轉(zhuǎn)肽酶(GGT)水平均顯著降低,同組治療前后差異具有統(tǒng)計學意義(P<0.05)。與對照組比較,治療后治療組血清ALT、AST、TBIL、GGT水平均顯著低于對照組,差異具有統(tǒng)計學意義(P<0.05)。治療后兩組血清透明質(zhì)酸(HA)、層黏連蛋白(LN)、Ⅲ型前膠原(PcⅢ)、Ⅳ型膠原(IV-C)水平均較治療前顯著降低,差異具有統(tǒng)計學意義(P<0.05)。與對照組比較,治療后治療組血清HA、LN、PCⅢ、IV-C水平均顯著低于對照組,差異具有統(tǒng)計學意義(P<0.05)。結(jié)論 注射用硫普羅寧聯(lián)合注射用促肝細胞生長素治療慢性乙型肝炎具有較好的臨床療效,能夠顯著改善肝功能,減輕肝纖維化的程度。

Objective To investigate the clinical effect of Tiopronin for injection combined with Hepatocyte Growth-promoting Factor for injection in treatment of chronic hepatitis B. Methods Patients (106 cases) with chronic hepatitis B in Shanghai Fengxian District Central Hospital from June 2014 to June 2015 were randomly divided into control and treatment groups, and each group had 53 cases. All patients in the two groups were treated with hypoglycemic therapy. The patients in the control group were iv administered with Hepatocyte Growth-promoting Factor for injection, 100 — 200 mg dissolving with 5% glucose injection 250 mL, once daily. The patients in the treatment group were iv administered with Tiopronin for injection at the basis of the control group, 0.2 mg dissolving with 5% glucose injection 250 mL, once daily. The patients in two groups were treated for 1 month. The clinical efficacy of the two groups was observed, and then the indexes of liver function and liver fibrosis of two groups before and after the treatment were detected and compared. Results After 1 month of treatment, the efficacies in the control and treatment groups were 81.1% and 96.2%, respectively, and there were differences between two groups (P < 0.05). After treatment, the levels of ALT, AST, TBIL, and GGT in two groups were significantly decreased, and the difference was statistically significant in the same group (P < 0.05). And these indicators in treatment group were lower than those in the control group, with significant difference between two groups (P < 0.05). After treatment, the levels of HA, LN, PCⅢ, and IV-C in two groups were obviously decreased, and the difference was statistically significant in the same group (P < 0.05). And these indicators in treatment group were lower than those in the control group, with significant difference between two groups (P < 0.05). Conclusion Tiopronin for injection combined with Hepatocyte Growth-promoting Factor for injection has good clinical effect in treatment of chronic hepatitis B, which can obviously improve liver function and relief the degree of liver fibrosis.